DYNLRB1 and influenza: These findings indicate that BLP could be utilized not only as a vaccine candidate targeting a single antigen (SARS-CoV-2 S or influenza HA protein) but also as a multivalent vaccine candidate containing both SARS-CoV-2 S and influenza HA proteins.